Evidence map

ArticleAnnals of internal medicine2023

In CKD, once-daily empagliflozin reduced progression of kidney disease or CV death at 2 y.

Y Diana Kwong et al.PubMed ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Full record →Abstract, authors, funding and every citing paper · PMID 36877974